Decoding Amgen's Options Activity: What's the Big Picture?
Decoding Amgen's Options Activity: What's the Big Picture?
In today's trading context, the average open interest for options of Amgen stands at 1066.0, with a total volume reaching 267.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Amgen, situated within the strike price corridor from $280.0 to $350.0, throughout the last 30 days.Financial giants have made a conspicuous bullish move on Amgen. Our analysis of options history for Amgen (NASDAQ:AMGN) revealed 8 unusual trades.
金融巨頭在安進表現出明顯的看好動作。我們對安進（納斯達克：AMGN）期權歷史的分析揭示了8筆飛凡的交易。
Delving into the details, we found 37% of traders were bullish, while 37% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $172,165, and 4 were calls, valued at $144,495.
深入細節，我們發現37%的交易者看好，而37%則表現出看淡的傾向。在我們觀察到的所有交易中，有4筆看跌，價值172,165美元，4筆看漲，價值144,495美元。
Projected Price Targets
預計價格目標
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $280.0 and $350.0 for Amgen, spanning the last three months.
在評估成交量和未平倉合約後，顯然主要市場參與者正關注安進的價格區間在280.0美元到350.0美元之間，持續了三個月。
Analyzing Volume & Open Interest
分析成交量和未平倉合約
In today's trading context, the average open interest for options of Amgen stands at 1066.0, with a total volume reaching 267.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Amgen, situated within the strike price corridor from $280.0 to $350.0, throughout the last 30 days.
在今天的交易環境中，安進期權的平均未平倉合約爲1066.0，總成交量達到267.00。附帶的圖表描繪了安進中高價值交易的看漲和看跌期權成交量及未平倉合約的進展，位於280.0美元到350.0美元的行權價區間，持續了過去30天。
Amgen Option Volume And Open Interest Over Last 30 Days
安進期權成交量和未平倉量在過去30天內的情況
Noteworthy Options Activity:
值得注意的期權活動：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | PUT | TRADE | BULLISH | 12/20/24 | $22.0 | $21.4 | $21.55 | $292.50 | $60.3K | 70 | 51 |
| AMGN | PUT | SWEEP | BEARISH | 12/20/24 | $21.8 | $21.4 | $21.5 | $292.50 | $45.1K | 70 | 51 |
| AMGN | CALL | SWEEP | BEARISH | 12/20/24 | $18.0 | $17.4 | $17.44 | $282.50 | $43.7K | 703 | 113 |
| AMGN | CALL | SWEEP | BULLISH | 01/17/25 | $20.5 | $19.85 | $20.5 | $280.00 | $40.9K | 1.7K | 7 |
| AMGN | PUT | TRADE | NEUTRAL | 01/17/25 | $56.1 | $53.95 | $55.05 | $335.00 | $38.5K | 310 | 7 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | 看跌 | 交易 | BULLISH | 12/20/24 | $22.0 | $21.4 | $21.55 | $292.50 | $60.3K | 70 | 51 |
| AMGN | 看跌 | SWEEP | 看淡 | 12/20/24 | $21.8美元 | $21.4 | 21.5美元 | $292.50 | $45.1K | 70 | 51 |
| AMGN | 看漲 | SWEEP | 看淡 | 12/20/24 | $18.0 | $17.4 | 17.44美元 | $282.50 | $43.7千美元 | 703 | 113 |
| AMGN | 看漲 | SWEEP | BULLISH | 01/17/25 | $20.5 | $19.85 | $20.5 | $280.00 | $40.9千 | 1.7K | 7 |
| AMGN | 看跌 | 交易 | 中立 | 01/17/25 | $56.1 | $53.95 | $55.05 | 335.00美元 | $38.5K | 310 | 7 |
About Amgen
關於安進
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
安進是生物技術製藥領域的領導者。旗艦藥物包括增加紅細胞計數的艾普畢與阿拉尼許、增強免疫系統的奈帕姆和奈烏細胞移植因子、以及針對炎症性疾病的恩布瑞爾和歐特茲拉。安進在2006年推出了首個癌症治療藥物Vectibix，並推出了增強骨密度的藥物Prolia/Xgeva（於2010年獲批）和Evenity（於2019年獲批）。對Onyx的收購增強了該公司在治療腫瘤領域的藥物組合，其中包括Kyprolis。最近推出的藥物包括Repatha（降低膽固醇）、Aimovig（緩解偏頭痛）、Lumakras（治療肺癌）以及Tezspire（治療哮喘）。2023年Horizon收購帶來了幾種罕見疾病藥物，其中包括治療甲狀腺眼病的Tepezza。安進還擁有不斷增長的生物類似物組合。
Following our analysis of the options activities associated with Amgen, we pivot to a closer look at the company's own performance.
在我們對安進的期權活動進行分析後，我們轉向更仔細地觀察公司自身的表現。
Where Is Amgen Standing Right Now?
目前安進的處境如何？
- With a trading volume of 2,464,150, the price of AMGN is up by 1.67%, reaching $284.63.
- Current RSI values indicate that the stock is may be approaching oversold.
- Next earnings report is scheduled for 76 days from now.
- 在成交量爲2,464,150的情況下，AMGN的價格上漲了1.67%，達到284.63美元。
- 當前RSI值表明該股票可能即將超賣。
- 下一個業績預計在76天后發佈。
Unusual Options Activity Detected: Smart Money on the Move
檢測到期權異動：智慧資金在行動。
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.
Benzinga Edge的期權異動模塊可以提前發現潛在的市場熱點。了解大筆的資金在您喜歡的股票上的倉位變動。點擊這裏獲取訪問權限。
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Amgen options trades with real-time alerts from Benzinga Pro.
期權交易具有更高的風險和潛在回報。精明的交易者通過不斷學習、調整策略、監控多個因子和密切關注市場走勢來管理這些風險。通過Benzinga Pro的實時提醒了解最新的安進期權交易。
譯文內容由第三人軟體翻譯。
